💥 Gate Square Event: #PTB Creative Contest# 💥
Post original content related to PTB, CandyDrop #77, or Launchpool on Gate Square for a chance to share 5,000 PTB rewards!
CandyDrop x PTB 👉 https://www.gate.com/zh/announcements/article/46922
PTB Launchpool is live 👉 https://www.gate.com/zh/announcements/article/46934
📅 Event Period: Sep 10, 2025 04:00 UTC – Sep 14, 2025 16:00 UTC
📌 How to Participate:
Post original content related to PTB, CandyDrop, or Launchpool
Minimum 80 words
Add hashtag: #PTB Creative Contest#
Include CandyDrop or Launchpool participation screenshot
🏆 Rewards:
🥇 1st
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.